The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to collaborate with the International Neuroendocrine Cancer Alliance (INCA) to share the results from the Survey of Challenges in Access to Diagnostics and Treatments for NET patients (SCAN). The SCAN is the most significant global compendium of data about neuroendocrine tumors (NETs) created to date. The hope is that this data will be used by health care professionals, patients and researchers around the world to advance NET care and treatments.
The SCAN is based on participation from more than 2,359 patients and 436 health care providers. Over the next eight months, NETRF will partner with INCA to share the results of the SCAN. For the month of April, the campaign explores access to treatment and care.
Key findings from the SCAN related to access to treatment include:
- Around the globe NET patients have to travel large distances, often over 250 km, just to see a specialist. Here in the U.S. that is the equivalent of 155 miles.
- A huge difference exists in the availability of the most used NET treatments between countries with advanced economies (AEs) and emerging developing economies. (EDEs). For example, peptide receptor radionuclide therapy is available for 57% of patients in AEs but for only 33% of those living in EDEs.
- Only a third of NET patients around the globe have access to a multidisciplinary team and specialists which are essential for a complicated disease such as NETs.
At NETRF, we believe that all patients’ lives matter, regardless of how much money they have or where they live in the world. We stand with INCA in their efforts to drive change and help improve patient outcomes. Learn more about INCA’s work to support Equal Access to Treatments and Care for All Patients.
We encourage you to review the infographics below detailing Access to Treatments & Care. Information is provided in 10 languages.
